Kidney Cancer
Research activity in kidney cancer focuses on metastatic renal cell carcinoma and treatment selection informed by molecular subgroups. The clinical interest includes immunotherapy with nivolumab and ipilimumab, as well as targeted therapy with tyrosine kinase inhibitors such as sunitinib and pazopanib.
- Renal cell carcinoma
- Immunotherapy
- Targeted therapy
- Molecular subgroup stratification
The sponsor’s work in this area is centered on comparing treatment approaches across biologically defined disease groups in advanced kidney malignancy.
Prostate Cancer
Another major area of interest is newly diagnosed prostate cancer with pelvic lymph node metastases, where research examines the role of androgen receptor inhibition with darolutamide alongside androgen deprivation therapy and radiotherapy. The therapeutic focus includes disease control in hormone-naïve prostate cancer with regional nodal involvement.
- Hormone-naïve prostate cancer
- Pelvic lymph node metastases
- Androgen deprivation therapy
- Radiotherapy
This research domain reflects interest in combined systemic and local treatment strategies for newly diagnosed advanced prostate disease.
